



U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
OFFICE OF INSPECTOR GENERAL

TO: Seema Verma, M.P.H.
Administrator
Centers for Medicare & Medicaid Services

FROM: Suzanne Murrin 
Deputy Inspector General
for Evaluation and Inspections

SUBJECT: *Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2019, OEI-03-19-00050*

This memorandum summarizes the results of the Office of Inspector General's (OIG) comparison of average sales prices (ASPs) and average manufacturer prices (AMPs) for the first quarter of 2019. By law, OIG must notify the Secretary of Health and Human Services if the ASP for a particular drug exceeds the drug's AMP by 5 percent or more. If that threshold is met, the Secretary may disregard the drug's ASP when setting the reimbursement amount and shall substitute the payment amount with the lesser of either the widely available market price or 103 percent of the AMP.

In April 2013, the Centers for Medicare & Medicaid Services (CMS) began making price substitutions in accordance with the November 2012 final rule specifying the circumstances under which AMP-based price substitutions shall occur. Pursuant to the rule, CMS substitutes 103 percent of the AMP for the ASP-based reimbursement amount when OIG identifies a drug code that exceeds the 5-percent threshold for 2 consecutive quarters or 3 of the previous 4 quarters. CMS lowers reimbursement amounts only when ASP and AMP comparisons are based on the same set of drug products (i.e., based on complete AMP data). To prevent CMS from inadvertently raising the Medicare reimbursement amount, a price substitution shall not be implemented if the substituted amount would exceed the ASP-based payment amount for the quarter in which the price substitution would take effect. Nor shall price substitutions be implemented for drugs that the Food and Drug Administration (FDA) identifies as being in short supply.

OIG found that in the first quarter of 2019, 11 drug codes met CMS's price substitution criteria by exceeding the 5-percent threshold for 2 consecutive quarters or 3 of the previous 4 quarters,

based on complete AMP data. OIG found one additional drug code that, based on complete AMP data, exceeded the 5-percent threshold. However, at the time of our analysis, FDA identified this drug code as being in short supply. Another three drug codes had ASPs that exceeded the AMPs by at least 5 percent in the first quarter of 2019, based on complete AMP data, but these drug codes did not meet other CMS price-substitution criteria.

We will provide you with the results of our pricing comparison for the first quarter of 2019, as well as the results for the 3 previous quarters. This information will be transmitted via our secure file transfer system.